☰

CF Plus Chemicals s.r.o.

Bridging research-grade chemistry and ADC clinical supply

Industry
Specialty Chemicals and Bioconjugation Services
Headquarters
Brno, Czech Republic
Public information as of
February 2026

A4BEE prepared this analysis from publicly available sources. It reflects our own reading of CF Plus Chemicals s.r.o.'s published strategy and is not endorsed by, or produced in cooperation with, CF Plus Chemicals s.r.o.. Company website

Strategic priorities

CF Plus Chemicals operates at the intersection of two product lines built on Second-Generation Togni Reagents: a catalog fluoroalkylation reagent range sold through Merck KGaA, Chemspace and eMolecules, and the CF LINK bioconjugation platform targeting Tryptophan residues for site-selective antibody-drug conjugate construction. The company is registered as a Czech s.r.o. at the BioVendor industrial campus at Karásek 1767/1 in Brno-Řečkovice, and traces its scientific lineage to ETH Zurich via its founder.

The CEO has publicly stated that production volumes do not exceed one kilogram per batch, which keeps the company inside the research-grade reagent market but outside the Phase II and Phase III clinical trial supply chain for ADCs. Strategic intent is to industrialise: scale Togni reagent manufacturing safely to multi-kilogram batches and produce bioconjugation services under GMP-capable documentation that ADC partners can file.

Industrialisation here runs on two data systems that have not yet been wired together. CF LINK verification relies on LC-MS/MS analysis (Liquid Chromatography-Tandem Mass Spectrometry, a protein-characterisation technique that fragments peptides and measures their masses) executed in academic tools such as MZmine and MSnLib at collaborator IMIC/BIOCEV labs, while batch production runs on paper or Excel in Brno. Bridging those two data paths into a regulatory-acceptable record is the work that lets the same chemistry enter clinical supply.

The strategic context is the Antibody-Drug Conjugate market, where regulators expect site-selective drug attachment to be demonstrated to specific residues on the antibody. CF Plus's competitive position rests on Tryptophan targeting (a residue present in roughly one percent of antibody positions), so its analytical proof to pharma partners is also the documentation a regulator will eventually ask to see.

Challenges we see

  • Operations Manufacturing

    Scaling hypervalent iodine synthesis past the kilogram mark

    Production volumes are explicitly limited to under one kilogram per batch due to the thermodynamic risks of hypervalent iodine synthesis, preventing participation in Phase II/III clinical trial supply chains.

    Scaling exothermic chemistry past the bench is not a linear exercise; reproducing the heat-transfer regime, dosing profile and mixing conditions of a successful gram-scale run inside a larger vessel is what has to be modelled before metal is committed.

  • Digital Integration

    Moving CF LINK bioconjugation verification into a compliant data path

    CF LINK bioconjugation verification relies on complex LC-MS/MS analysis using academic tools like MZmine and MSnLib that require manual interpretation and lack FDA 21 CFR Part 11 compliance (the US rule on electronic records and signatures for regulated submissions).

    Where a verification result is produced by a research tool operated by an individual, the same finding has to be re-derivable from the underlying data; placing the workflow on a deterministic instrument-to-record pipeline is what makes the result fileable.

  • Digital Operations

    Reconnecting with end-users behind the distributor channel

    Heavy reliance on distributors (Merck, Chemspace, eMolecules) severs direct connection with end-researchers, preventing identification of high-value service leads.

    Where reagent sales are intermediated, the end-researcher relationship sits with the distributor; a thin instrumented overlay on the bottle that returns a consented researcher profile recovers that relationship without rebuilding the distribution model.

  • Compliance Regulatory

    Generating GMP-grade evidence from research-grade production

    Operating in research-grade production while co-located on a GMP-capable campus creates a documentation and traceability gap as the company pivots toward ADC supply chain participation.

    GMP evidence is generated by the production system rather than compiled for the auditor; the question for the production system is whether every parameter, sample and deviation it captured is also retained in an inspectable form without batch sheets being assembled afterwards.

  • Operations Operations

    Distributing founder-led process knowledge across the team

    Critical IP and process knowledge concentrated in the founder and academic collaborators rather than systematized in scalable documentation.

    Where the route to a successful synthesis lives primarily in the head of one scientist, onboarding a new chemist to that route is a multi-month reconstruction; an indexed, queryable record collapses that ramp to a search.

Opportunities, by urgency and business impact

Each bubble is one opportunity, numbered to match the list below. Further right means it bites sooner; higher means a bigger effect on the business. A bigger bubble means a bigger implementation effort.

Source: A4BEE analysis of public sources

  1. Modelling heat-transfer regimes before scaling hypervalent iodine chemistry

    Scale-up of Togni reagent synthesis requires precise control of exothermic reactions; current lab-scale methods cannot safely transfer to pilot-plant volumes without thermal management modelling.

    Process simulation using CFD (Computational Fluid Dynamics, numerical modelling of fluid flow and heat transfer) and thermodynamic modelling lets cooling strategies, dosing profiles and vessel configurations be evaluated at 10-50 kg scale before any material is committed, with the safety envelope derived from physics rather than from the first failed batch.

    • CEO statement, BioVendor interview archive
    • Patent EP2982672A1, hypervalent iodine synthesis routes

  2. Putting CF LINK verification on a regulated analytical pipeline

    Bioconjugation verification generates massive MS (Mass Spectrometry, measuring mass-to-charge ratios of ionised molecules) datasets analysed with academic software lacking validation, automation, and the regulatory compliance features required for ADC submissions.

    A regulated cloud pipeline that ingests raw LC-MS/MS output, runs containerised versions of the academic algorithms, and emits a traceable Certificate of Conjugation turns a manual expert process into a result the same person can re-issue from the underlying data on demand.

    • Collaboration documentation between CF Plus and the collaborator group at BIOCEV
    • Public methodology notes on MZmine and MSnLib

  3. Reconnecting end-researcher signals to the commercial team

    Distributor-based sales model prevents tracking end-user identity, usage patterns, and research applications, blocking targeted marketing of high-margin services.

    Connected packaging codes (QR/NFC, machine-readable labels printed on the bottle) linking to a customer content portal capture consented researcher registration in exchange for protocols and troubleshooting guides, returning the end-user signal the distributor currently absorbs.

    • Distribution network: Merck KGaA, Chemspace, eMolecules, Biortus USA, Biosynth UK
    • Company publications on customer-facing protocols

  4. Generating GMP-aligned batch records inside the existing research process

    Research-grade production lacks the digital batch records and traceability systems required for GMP audits, blocking the pivot to ADC clinical trial supply.

    A lightweight MES (Manufacturing Execution System, software that records and controls production operations step by step) layer that captures what is already happening on the bench into a per-batch electronic record, with raw-material genealogy and parameter traceability, prepares the operation for GMP certification without rebuilding the workflow it sits on top of.

    • BioVendor industrial campus partnership, 2018
    • Public ADC regulatory framework expectations (FDA/EMA)

  5. Drafting routine GMP and regulatory documents from source records

    Deviation summaries, change controls, validation reports, batch records and grant deliverables all consume specialist time, and much of that time goes on assembling and checking documents rather than on the technical judgement inside them.

    Narrow AI agents can draft the first version of a deviation summary or change-control form from the production and quality records, check a document against its template before a reviewer picks it up, and find every controlled document a standards change affects, with a named scientist approving every output before release.

    • Public descriptions of CF Plus regulatory footprint
    • EU and US frameworks on ADC and active-substance documentation

What we'd propose

  • Digital CDMO

    Process safety digital twin for hypervalent iodine scale-up

    We build a CFD and thermodynamic model of the company's hypervalent iodine synthesis, run virtual experiments on cooling, dosing and vessel configurations at 10-50 kg scale, and return a safety envelope that becomes the basis for the pilot-plant design rather than a reconstruction after the first incident.

    • Reaction thermodynamic model

      Heat and dosing modelled before metal

      Build a CFD-based model of heat evolution, mixing kinetics and dosing profile for the company's Second-Generation Togni route at 10-50 kg scale, so the candidate vessel configurations can be screened in simulation rather than by trial batch.

    • Virtual scale-up scenarios

      Cooling and geometry scenarios

      Run virtual experiments on vessel geometry, cooling strategy and dosing rate, recording the predicted peak temperature and deviation envelope for each configuration, which becomes the design basis for the pilot-plant retrofit.

    • Instrumented reactor monitoring

      Process parameters on the running batch

      Connect temperature, pressure and stirring torque instrumentation to the reactor so the running batch is compared against the simulated envelope, with deviation alerts raised on the parameters the model flagged as critical for that synthesis.

    • Scale-up design is anchored in physics rather than in the first failed batch.
    • The pilot envelope is documented before procurement, shortening the iteration cycle.
    • Safety evidence is generated alongside the simulation rather than after a safety review.

    We've done this before

    See how we do Digital CDMO
  • Digital Lab

    Regulated analytical pipeline for CF LINK bioconjugation verification

    We bring raw LC-MS/MS data from the analytical instruments onto a validated cloud pipeline, run hardened versions of MZmine and MSnLib against it, and emit a Certificate of Conjugation that carries its own audit trail and is reproducible from the underlying data.

    • Instrument-to-cloud data ingestion

      Raw MS data captured at source

      Establish a secure ingestion path from the LC-MS/MS instruments at the BIOCEV partner labs through to the processing environment, with file integrity verification and instrument metadata attached so the provenance of every result is preserved.

    • Containerised algorithm execution

      Academic tools under version control

      Wrap the MZmine and MSnLib workflows in containerised, version-controlled pipelines so the same analysis runs identically each time, and the algorithm version is recorded with every output.

    • Certificate of Conjugation with audit trail

      Verification result, replayable

      Generate a Certificate of Conjugation that records the input files, parameters, algorithm versions and result, with the underlying data retained so the verification can be replayed end-to-end during an ADC partner's technical review.

    • Verification results become reproducible from their own data, removing dependence on the analyst on duty.
    • ADC partners receive a documented Certificate of Conjugation rather than a manually written report.
    • The same pipeline is reusable across Togni reagent QC and bioconjugation verification work.

    We've done this before

    See how we do Digital Lab
  • Enterprise AI

    Connected packaging for end-researcher signals

    We add a thin connected-packaging layer to the reagent bottles sold through distributors, surface a customer content portal in exchange for opt-in registration, and pass consented end-researcher signals back to the commercial and applications teams.

    • Connected labelling on reagent bottles

      Bottles that surface protocols

      Place QR or NFC (Near-Field Communication, contactless chip-readable labels) codes on reagent bottles that route the researcher to a content portal carrying protocols, troubleshooting guides and safety data, with consent-driven registration that captures the application context.

    • Consent and identity layer

      Researcher opt-in, not surveillance

      Handle consent, data minimisation and researcher identity in line with GDPR (the EU General Data Protection Regulation) so the signal collected is opt-in, minimal and disclosed, with the option to remain anonymous if the chemist prefers.

    • Service-lead signal to the commercial team

      End-user signal without breaking distribution

      Aggregate the consented researcher and application data into a lead-scoring view for the commercial team, surfacing high-value bioconjugation service enquiries without rebuilding the distributor relationship that delivers the volumes.

    • The researcher signal the distributor absorbs comes back to the commercial team in opt-in form.
    • Bioconjugation service enquiries surface from existing reagent customers without changing the distribution model.
    • Protocol access is exchanged for a researcher profile that the applications team can act on.

    We've done this before

    See how we do Enterprise AI
  • Digital CDMO

    GMP-aligned batch records inside the existing research process

    We add a lightweight MES layer onto the production process that captures raw-material genealogy, process parameters and operator actions into a per-batch electronic record, producing GMP-aligned evidence without changing how the bench chemistry is run.

    • Digital batch record capture

      Per-batch electronic record

      Replace paper and Excel batch sheets with an electronic record that captures what was actually done on the bench, with operator identity, timestamps and parameter values attached to each entry.

    • Raw-material genealogy

      Traceability from receipt to ship

      Link the materials received from suppliers to the batch record and through to the shipped reagent, so a partner audit can move from the bottle back to the input material with the data already attached.

    • GMP-aligned workflows without scale overhead

      Compliance by configuration

      Configure the MES for research-grade operations today and switch the same workflow into a GMP-aligned mode once the certification target is set, without rebuilding the bench interaction.

    • Batch records are produced by the run, not assembled after it.
    • The production data needed for a future GMP audit is already retained on the day the batch is made.
    • The same workflow scales from research-grade to certified production without a platform change.

    We've done this before

    See how we do Digital CDMO
  • Agents

    AI agents for routine GMP and regulatory document work

    We deploy narrow, reviewable agents that take the repetitive part of the documentation load: drafting the first version of a deviation summary or change-control form from the production records, checking a draft against its template before it reaches a reviewer, and finding every controlled document that a standards change touches. A named scientist approves every output.

    • Drafting from source records

      First drafts from the data

      Generate the first version of a deviation summary, change-control form or batch-record excerpt directly from the MES and quality records, so the scientist edits and judges rather than assembles.

    • Template and completeness check

      Gaps found before review

      Check a document against its template and the site's own checklist before it enters the review queue, surfacing missing sections, inconsistencies and references that need to be added.

    • Change-impact search across the document set

      Which documents a change touches

      When a standard, monography or specification changes, retrieve every controlled document that references it and rank them by how directly they are affected, so the update scope is known on day one of the change.

    • Scientists spend review time on judgement rather than on assembly.
    • Documents arrive at review complete against their template.
    • Every output is traceable to the records it came from and signed off by a named scientist.

    We've done this before

    See how we do Agents

Digital maturity: today and target

Scored out of 100 across six dimensions. The target is what CF Plus Chemicals s.r.o.'s own published ambition implies — not a perfect score.

Source: A4BEE analysis of public sources
Process automation 25 → 70
Hypervalent iodine synthesis and bioconjugation services both run as bench-scale operations with limited automated control, and the move toward process simulation is the entry point to scale the chemistry beyond the current kilogram ceiling.
Data integration 30 → 80
MS verification data lives in academic tools on partner-lab workstations while batch production data lives in paper and Excel on Brno benches; bringing both into one inspectable record is the precondition for any future regulatory filing.
Analytics and AI 22 → 68
Analytical insight today is the result of an individual's interpretation of an MZmine or MSnLib run; regulated analytical pipelines and knowledge agents would move that insight into something reviewers and regulators can examine.
Equipment connectivity 32 → 75
Instruments are connected for research workflows today, but the data path from each instrument to a durable record is not standardised; instrument-level OPC UA (Open Platform Communications Unified Architecture, a vendor-neutral industrial communication standard) and metadata contracts would close that gap.
Regulatory readiness 28 → 85
Research-grade production meets the reagent market today; the move into ADC clinical supply requires GMP-aligned batch records and 21 CFR Part 11-compliant analytical records, and that documentation gap is what the page is built to close.
Knowledge management 24 → 65
The synthesis and verification routes live primarily in the heads of the founder and academic collaborators; an indexed record of those routes would shorten new-chemist onboarding and stabilise the team against turnover.

Check this yourself

Our Service Portal has free self-assessments and market comparisons. These are the ones that line up with what we've read above — no sales call required.

Think we've read this right?

Talk to us

Related reading

This is an independent analysis prepared by A4BEE from publicly available information as of February 2026. It reflects A4BEE's own interpretation and opinion, is not affiliated with, endorsed by, or verified with CF Plus Chemicals s.r.o., and may be incomplete or inaccurate. All company names and trademarks are the property of their respective owners. To request a correction or removal, contact [email protected].